Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.

ABSTRACT:

Background

Drug development in sarcoma has been hampered by the rarity and heterogeneity of the disease and lack of predictive biomarkers to therapies. We assessed protein expression and gene alterations in a large number of bone and soft tissue sarcomas in order to categorize the molecular alterations, identify predictive biomarkers and discover new therapeutic targets.

Methods

Data from sarcoma specimens profiled for protein expression, gene amplification/translocation and DNA sequencing was reviewed.

Results

2539 sarcoma specimens of 22 subtypes were included. TOPO2A was the most overexpressed protein at 52.8%. There was overexpression or loss of other sarcoma relevant proteins such as SPARC, PTEN and MGMT. Approximately 50% of the sarcomas expressed PD-L1 by IHC a

SUBMITTER: Movva S 

PROVIDER: S-EPMC4494935 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature